An Open-Label, Single-Dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Dazucorilant (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
Most Recent Events
- 21 Apr 2025 New trial record